Gilead Sciences Inc. (NASDAQ:GILD): Piper Jaffray plans for shares of Gilead to trade down following GlaxoSmithKline (NYSE:GSK) reported this morning that the SINGLE Phase 3 study of its HIV integrase inhibitor showed superiority to Atripla in treatment nave HIV patients. Piper thinks GSK conducted a better study than Gilead, but that it does not have a better product. Piper Jaffray announced it would buy Gilead shares.
Don’t Miss: Are Traders NERVOUS About This Drug Stock?
General Mills Inc. (NYSE:GIS): BMO Capital, following attendance at General Mills’ investor gathering, thinks the company has a good pipeline of new products. BMO believes the company can get back market share in Greek yogurt and effect long-term growth via international expansion. BMO holds to a $43 target and Outperform rating on General Mills stock.
Theravance Inc.‘s (NASDAQ:THRX) price target has been boosted by Piper Jaffray due to its positive LAMA/LABA Phase III data and maintains an Overweight rating on the stock.
Helmerich & Payne Inc. (NYSE:HP): Following Helmerich & Payne’s reduction of its Q3 margin outlook for its American land segment, Argus reduced its estimates but plans for the company to benefit from the expansion in unconventional drilling activity. The firm believes H&P is one of the best managed companies in its coverage universe, and is leaving the stock on its Focus List.
Halliburton Company (NYSE:HAL): In part thanks to low energy prices, Argus lowered its estimates for Halliburton and thinks that the company is encountering more challenges in passing along higher costs. But the firm notes that the company’s share price does not mirror its fundamentals, and reiterates a Buy rating for shares.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.